Evidence map›Paper›PMID 27959614›Full record

Observational studyThe New England journal of medicine2016

Diabetes and Cause-Specific Mortality in Mexico City.

Jesus Alegre-Díaz, William Herrington, Malaquías López-Cervantes, Louisa Gnatiuc, Raul Ramirez, Michael Hill, Colin Baigent, Mark I McCarthy, Sarah Lewington, Rory Collins and 5 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 5 pooled it
25.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 5 syntheses or guidelines pooled it, 276 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Type 2 diabetes genetics in 125,000 admixed adults from Mexico City.medRxiv : the preprint server for health sciences · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Comprehensive study of associated factors with Type 2 Diabetes in Mexico: protocol.Revista medica del Instituto Mexicano del Seguro Social · 2025
    Observational
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Jesus Alegre-Díaz *School of Medicine, National Autonomous University of Mexico (UNAM), Mexico City.
William Herrington *Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), University of Oxford, Oxford, United Kingdom.
Malaquías López-CervantesSchool of Medicine, National Autonomous University of Mexico (UNAM), Mexico City.
Louisa GnatiucClinical Trial Service Unit and Epidemiological Studies Unit (CTSU), University of Oxford, Oxford, United Kingdom.
Raul RamirezSchool of Medicine, National Autonomous University of Mexico (UNAM), Mexico City.
Michael HillClinical Trial Service Unit and Epidemiological Studies Unit (CTSU); Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom.
Colin BaigentClinical Trial Service Unit and Epidemiological Studies Unit (CTSU); Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom.
Mark I McCarthyNuffield Department of Population Health, and the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), Nuffield Department of Medicine , University of Oxford, Oxford, United Kingdom.
Sarah LewingtonClinical Trial Service Unit and Epidemiological Studies Unit (CTSU); Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom.
Rory CollinsClinical Trial Service Unit and Epidemiological Studies Unit (CTSU), University of Oxford, Oxford, United Kingdom.
Gary WhitlockClinical Trial Service Unit and Epidemiological Studies Unit (CTSU), University of Oxford, Oxford, United Kingdom.
Roberto Tapia-ConyerSchool of Medicine, National Autonomous University of Mexico (UNAM), Mexico City.
Richard PetoClinical Trial Service Unit and Epidemiological Studies Unit (CTSU), University of Oxford, Oxford, United Kingdom.
Pablo Kuri-Morales *School of Medicine, National Autonomous University of Mexico (UNAM), Mexico City.
Jonathan R Emberson *Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU); Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom.
University of Oxford · GB

Funding

Cancer Research UK 16896Medical Research Council MC_U137686855Medical Research Council MC_UU_12026/3Wellcome Trust
6 · The paper itself

Abstract

backgroundMost large, prospective studies of the effects of diabetes on mortality have focused on high-income countries where patients have access to reasonably good medical care and can receive treatments to establish and maintain good glycemic control. In those countries, diabetes less than doubles the rate of death from any cause. Few large, prospective studies have been conducted in middle-income countries where obesity and diabetes have become common and glycemic control may be poor.

methodsFrom 1998 through 2004, we recruited approximately 50,000 men and 100,000 women 35 years of age or older into a prospective study in Mexico City, Mexico. We recorded the presence or absence of previously diagnosed diabetes, obtained and stored blood samples, and tracked 12-year disease-specific deaths through January 1, 2014. We accepted diabetes as the underlying cause of death only for deaths that were due to acute diabetic crises. We estimated rate ratios for death among participants who had diabetes at recruitment versus those who did not have diabetes at recruitment; data from participants who had chronic diseases other than diabetes were excluded from the main analysis.

resultsAt the time of recruitment, obesity was common and the prevalence of diabetes rose steeply with age (3% at 35 to 39 years of age and >20% by 60 years of age). Participants who had diabetes had poor glycemic control (mean [±SD] glycated hemoglobin level, 9.0±2.4%), and the rates of use of other vasoprotective medications were low (e.g., 30% of participants with diabetes were receiving antihypertensive medication at recruitment and 1% were receiving lipid-lowering medication). Previously diagnosed diabetes was associated with rate ratios for death from any cause of 5.4 (95% confidence interval [CI], 5.0 to 6.0) at 35 to 59 years of age, 3.1 (95% CI, 2.9 to 3.3) at 60 to 74 years of age, and 1.9 (95% CI, 1.8 to 2.1) at 75 to 84 years of age. Between 35 and 74 years of age, the excess mortality associated with previously diagnosed diabetes accounted for one third of all deaths; the largest absolute excess risks of death were from renal disease (rate ratio, 20.1; 95% CI, 17.2 to 23.4), cardiac disease (rate ratio, 3.7; 95% CI, 3.2 to 4.2), infection (rate ratio, 4.7; 95% CI, 4.0 to 5.5), acute diabetic crises (8% of all deaths among participants who had previously diagnosed diabetes), and other vascular disease (mainly stroke). Little association was observed between diabetes and mortality from cirrhosis, cancer, or chronic obstructive pulmonary disease.

conclusionsIn this study in Mexico, a middle-income country with high levels of obesity, diabetes was common, glycemic control was poor, and diabetes was associated with a far worse prognosis than that seen in high-income countries; it accounted for at least one third of all deaths between 35 and 74 years of age. (Funded by the Wellcome Trust and others.).

Indexed as

Cause of DeathAdultAgedAge of OnsetDiabetes MellitusFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMexicoMiddle AgedPrevalencePrognosisGlycated Hemoglobin

Identifiers

PMID27959614
PMCPMC5215048
OpenAlexW2549876660

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.